Showing 2637 results
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Release /First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal…
- Media Release /Production and phased deliveries of patient doses resumed in early June Screening and enrollment have restarted for 177Lu-PSMA-617 and Lutathera® clinical trials Expanding radioligand therapy…
Pagination
- ‹ Previous page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- …
- 264
- › Next page